Technical Analysis for AGIO - Agios Pharmaceuticals, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week Closing High | Bullish | 0.00% | |
Earnings Movers | Other | 0.00% | |
Gapped Up | Strength | 0.00% | |
Up 3 Days in a Row | Strength | 0.00% | |
Up 4 Days in a Row | Strength | 0.00% | |
Up 5 Days in a Row | Strength | 0.00% | |
Earnings Movers | Other | 3.05% | |
Up 3 Days in a Row | Strength | 3.05% | |
Up 4 Days in a Row | Strength | 3.05% | |
Gapped Up | Strength | 4.89% |
Alert | Time |
---|---|
60 Minute Opening Range Breakout | about 23 hours ago |
Up 3% | about 23 hours ago |
Rose Above Previous Day's High | about 23 hours ago |
Up 2% | about 23 hours ago |
Up 1% | about 23 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/14/2024
Agios Pharmaceuticals, Inc. Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Its products include AG-221, an oral inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations, as well as for the Type II D-2 hydroxyglutaric aciduria treatment; AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations; and enzyme glutaminase that converts the nutrient glutamine into the metabolite glutamate. The company's products also comprise AG-348, an oral small molecule activator of PKR enzyme for the treatment of patients with pyruvate kinase deficiency. It has a collaboration agreement with Celgene Corporation. The company was founded in 2007 and is based in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Acid Hydrogen Metabolism Organic Chemistry Glutamate Inborn Errors Of Metabolism Pyruvate Kinase Deficiency
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 35.5 |
52 Week Low | 19.795 |
Average Volume | 657,715 |
200-Day Moving Average | 26.00 |
50-Day Moving Average | 30.78 |
20-Day Moving Average | 32.56 |
10-Day Moving Average | 33.64 |
Average True Range | 1.28 |
RSI (14) | 70.24 |
ADX | 37.25 |
+DI | 34.24 |
-DI | 10.62 |
Chandelier Exit (Long, 3 ATRs) | 31.65 |
Chandelier Exit (Short, 3 ATRs) | 32.54 |
Upper Bollinger Bands | 35.66 |
Lower Bollinger Band | 29.45 |
Percent B (%b) | 0.92 |
BandWidth | 19.07 |
MACD Line | 1.10 |
MACD Signal Line | 0.99 |
MACD Histogram | 0.1056 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 36.73 | ||||
Resistance 3 (R3) | 36.60 | 35.97 | 36.47 | ||
Resistance 2 (R2) | 35.97 | 35.57 | 36.03 | 36.38 | |
Resistance 1 (R1) | 35.57 | 35.33 | 35.77 | 35.70 | 36.30 |
Pivot Point | 34.94 | 34.94 | 35.04 | 35.00 | 34.94 |
Support 1 (S1) | 34.54 | 34.54 | 34.74 | 34.67 | 34.06 |
Support 2 (S2) | 33.91 | 34.30 | 33.97 | 33.98 | |
Support 3 (S3) | 33.51 | 33.91 | 33.89 | ||
Support 4 (S4) | 33.64 |